Antibiotic use doesn’t appear to disrupt the effectiveness of the immune checkpoint inhibitor durvalumab in advanced biliary tract cancer, according to a new analysis of TOPAZ-1 clinical trial data.
MDedge News
Antibiotic use doesn’t appear to disrupt the effectiveness of the immune checkpoint inhibitor durvalumab in advanced biliary tract cancer, according to a new analysis of TOPAZ-1 clinical trial data.
MDedge News
